Skip to search formSkip to main contentSkip to account menu

CK 1827452

Known as: CK-1827452 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

omecamtiv mecarbil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… 
2008
2008
The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure (10/8/08)
2006
2006
Abstract 2169: The Selective Cardiac Myosin Activator, CK-1827452, a Calcium-Independent Inotrope, Increases Left Ventricular Systolic Function by Increasing Ejection Time Rather than the Velocity of…
Introduction: Current inotropes increase contractility by raising intracellular Ca 2+ , which increases heart rate and O 2… 
2006
2006
Activating Cardiac Myosin, a Novel Inotropic Mechanism To Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure
2006
2006
In Vitro and In Vivo Characterization of CK-1827452, a Selective Cardiac Myosin Activator
2006
2006
The Selective Cardiac Myosin Activator, CK-1827452, Increases Left Ventricular Systolic Function by Increasing Ejection Time: Results of a First-in-Human Study of a Unique and Novel Mechanism
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)